Scientific Information Page
Erlotinib is a standard of care treatment for locally advanced or metastatic EGFR mutation-positive (Mut+) NSCLC.
Erlotinib is recommended by all major international clinical guidelines (including ESMO1, NCCN2 and CSCO3) for the first-line treatment of NSCLC with locally advanced or metastatic EGFR activating mutations.
Erlotinib plus bevacizumab is a treatment option for EGFR Mut+ NSCLC.
Erlotinib combined with the anti-angiogenic and anti-vascular bevacizumab is also a guideline-recommended first-line treatment option for unresectable advanced, metastatic or recurrent EGFR Mut+ NSCLC.1,3
Please click below for more information on key erlotinib clinical trials, as well as real-world evidence and retrospective analyses.
Please note; in some countries the combination of erlotinib plus bevacizumab may not be registered or reimbursed